SAN DIEGO, June 24, 2011 /PRNewswire/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced ...

BOSTON (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced ...

Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...

SAN FRANCISCO (MarketWatch) - Eli Lilly and Co. and Amylin Pharmaceuticals Inc. on Saturday said their Byetta injection treatment was shown to lower blood glucose levels for people with Type II ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...

SAN FRANCISCO (MarketWatch) - Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after Friday's closing bell said the Food and Drug Administration has approved Byetta injection as an add-on therapy to ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...

The FDA has approved Byetta (exenatide injection, from Amylin and Lilly), a GLP-1 receptor agonist, for use as monotherapy along with diet and exercise to improve glycemic control in adults with type ...